Abstract
Standard therapeutic approaches of cytotoxics and radiation in cancer are not only highly toxic, but also of limited efficacy in treatment of a significant number of cancer patients. The molecular analysis of the cancer genomes have shown a remarkable complexity and pointed to key genomic and epigenomic alterations in cancer. These discoveries are paving the way for targeted therapy approaches. However, although there are a large number of potential targets, only a few can regulate key cellular functions and intersect multiple signaling networks. The Aurora kinase family members (A, B, and C) are a collection of highly related and conserved serine-threonine kinases that fulfill these criteria, being key regulators of mitosis and multiple signaling pathways. Alterations in Aurora kinase signaling are associated with mitotic errors and have been closely linked to chromosomal aneuploidy in cancer cells. Several studies have shown amplification and/or overexpression of Aurora kinase A and B in hematologic malignancies and solid tumors. Over the past several years, Aurora kinases have become attractive targets. Several ongoing clinical trials and bench-based research are assessing the unique therapeutic potential of Aurora-based targeted therapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 268-278 |
| Number of pages | 11 |
| Journal | Molecular Cancer Therapeutics |
| Volume | 9 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 1 2010 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Aurora kinase inhibitors - Rising stars in cancer therapeutics? / Dar, Altaf A.; Goff, Laura W.; Majid, Shahana; Berlin, Jordan; El-Rifai, Wael.
In: Molecular Cancer Therapeutics, Vol. 9, No. 2, 01.02.2010, p. 268-278.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Aurora kinase inhibitors - Rising stars in cancer therapeutics?
AU - Dar, Altaf A.
AU - Goff, Laura W.
AU - Majid, Shahana
AU - Berlin, Jordan
AU - El-Rifai, Wael
PY - 2010/2/1
Y1 - 2010/2/1
N2 - Standard therapeutic approaches of cytotoxics and radiation in cancer are not only highly toxic, but also of limited efficacy in treatment of a significant number of cancer patients. The molecular analysis of the cancer genomes have shown a remarkable complexity and pointed to key genomic and epigenomic alterations in cancer. These discoveries are paving the way for targeted therapy approaches. However, although there are a large number of potential targets, only a few can regulate key cellular functions and intersect multiple signaling networks. The Aurora kinase family members (A, B, and C) are a collection of highly related and conserved serine-threonine kinases that fulfill these criteria, being key regulators of mitosis and multiple signaling pathways. Alterations in Aurora kinase signaling are associated with mitotic errors and have been closely linked to chromosomal aneuploidy in cancer cells. Several studies have shown amplification and/or overexpression of Aurora kinase A and B in hematologic malignancies and solid tumors. Over the past several years, Aurora kinases have become attractive targets. Several ongoing clinical trials and bench-based research are assessing the unique therapeutic potential of Aurora-based targeted therapy.
AB - Standard therapeutic approaches of cytotoxics and radiation in cancer are not only highly toxic, but also of limited efficacy in treatment of a significant number of cancer patients. The molecular analysis of the cancer genomes have shown a remarkable complexity and pointed to key genomic and epigenomic alterations in cancer. These discoveries are paving the way for targeted therapy approaches. However, although there are a large number of potential targets, only a few can regulate key cellular functions and intersect multiple signaling networks. The Aurora kinase family members (A, B, and C) are a collection of highly related and conserved serine-threonine kinases that fulfill these criteria, being key regulators of mitosis and multiple signaling pathways. Alterations in Aurora kinase signaling are associated with mitotic errors and have been closely linked to chromosomal aneuploidy in cancer cells. Several studies have shown amplification and/or overexpression of Aurora kinase A and B in hematologic malignancies and solid tumors. Over the past several years, Aurora kinases have become attractive targets. Several ongoing clinical trials and bench-based research are assessing the unique therapeutic potential of Aurora-based targeted therapy.
UR - http://www.scopus.com/inward/record.url?scp=76649120544&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=76649120544&partnerID=8YFLogxK
U2 - 10.1158/1535-7163.MCT-09-0765
DO - 10.1158/1535-7163.MCT-09-0765
M3 - Review article
C2 - 20124450
AN - SCOPUS:76649120544
VL - 9
SP - 268
EP - 278
JO - Molecular Cancer Therapeutics
JF - Molecular Cancer Therapeutics
SN - 1535-7163
IS - 2
ER -